98 related articles for article (PubMed ID: 27077771)
41. CTLA-4, PD-1 and TIM-3 expression predominantly downregulated in MS patients.
Mohammadzadeh A; Rad IA; Ahmadi-Salmasi B
J Neuroimmunol; 2018 Oct; 323():105-108. PubMed ID: 30196822
[TBL] [Abstract][Full Text] [Related]
42. [Expression and Significance of PD-1 and ICOS in Patients with Primary Immune Thrombocytopenia].
Fu Z; Qu W; Shao ZH; Wang HQ; Xing LM; Dong XF; Liu ZY; Li XN; Zhang Y; Ding SX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1170-1175. PubMed ID: 35981379
[TBL] [Abstract][Full Text] [Related]
43. Elevated Semaphorin 5A correlated with Th1 polarization in patients with chronic immune thrombocytopenia.
Lyu M; Li Y; Hao Y; Sun T; Liu W; Lyu C; Fu R; Li H; Xue F; Liu X; Zhang L; Yang R
Thromb Res; 2015 Nov; 136(5):859-64. PubMed ID: 26272304
[TBL] [Abstract][Full Text] [Related]
44. Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions.
Moret FM; van der Wurff-Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA
Arthritis Res Ther; 2014 Nov; 16(6):497. PubMed ID: 25433812
[TBL] [Abstract][Full Text] [Related]
45. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
46. Increased PD-1 on CD4(+)CD28(-) T cell and soluble PD-1 ligand-1 in patients with T2DM: association with atherosclerotic macrovascular diseases.
Shi B; Du X; Wang Q; Chen Y; Zhang X
Metabolism; 2013 Jun; 62(6):778-85. PubMed ID: 23398844
[TBL] [Abstract][Full Text] [Related]
47. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
48. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection.
Raziorrouh B; Ulsenheimer A; Schraut W; Heeg M; Kurktschiev P; Zachoval R; Jung MC; Thimme R; Neumann-Haefelin C; Horster S; Wächtler M; Spannagl M; Haas J; Diepolder HM; Grüner NH
Gastroenterology; 2011 Oct; 141(4):1422-31, 1431.e1-6. PubMed ID: 21763239
[TBL] [Abstract][Full Text] [Related]
49. Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1.
Chen WJ; Hu XF; Yan M; Zhang WY; Mao XB; Shu YW
Atherosclerosis; 2016 Jan; 244():108-12. PubMed ID: 26615520
[TBL] [Abstract][Full Text] [Related]
50. Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway.
Zhang SA; Niyazi HE; Hong W; Tuluwengjiang GL; Zhang L; Zhang Y; Su WP; Bao YX
Tumour Biol; 2017 Mar; 39(3):1010428317692237. PubMed ID: 28351328
[TBL] [Abstract][Full Text] [Related]
51. PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Joseph RW; Millis SZ; Carballido EM; Bryant D; Gatalica Z; Reddy S; Bryce AH; Vogelzang NJ; Stanton ML; Castle EP; Ho TH
Cancer Immunol Res; 2015 Dec; 3(12):1303-7. PubMed ID: 26307625
[TBL] [Abstract][Full Text] [Related]
52. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.
Ansari MJ; Salama AD; Chitnis T; Smith RN; Yagita H; Akiba H; Yamazaki T; Azuma M; Iwai H; Khoury SJ; Auchincloss H; Sayegh MH
J Exp Med; 2003 Jul; 198(1):63-9. PubMed ID: 12847137
[TBL] [Abstract][Full Text] [Related]
53. Value of vanin-1 assessment in adult patients with primary immune thrombocytopenia.
Elsalakawy WA; Ali MA; Hegazy MG; Farweez BA
Platelets; 2014; 25(2):86-92. PubMed ID: 23534352
[TBL] [Abstract][Full Text] [Related]
54. Phenotypic Characteristics of PD-1 and CTLA-4 Expression in Symptomatic Acute Hepatitis A.
Cho H; Kang H; Kim CW; Kim HY; Jang JW; Yoon SK; Lee CD
Gut Liver; 2016 Mar; 10(2):288-94. PubMed ID: 26347518
[TBL] [Abstract][Full Text] [Related]
55. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
56. [Expression of programmed death-1 and programmed death ligand-1 in the peripheral T-lymphocytes from patients with chronic periodontitis].
Zhu D; Liu F; Dai F; Luo X; Hong B
Zhonghua Kou Qiang Yi Xue Za Zhi; 2014 Apr; 49(4):216-9. PubMed ID: 24969595
[TBL] [Abstract][Full Text] [Related]
57. Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Shosu K; Sakurai M; Inoue K; Nakagawa T; Sakai H; Morimoto M; Okuda M; Noguchi S; Mizuno T
In Vivo; 2016; 30(3):195-204. PubMed ID: 27107075
[TBL] [Abstract][Full Text] [Related]
58. Role of DNA methyltransferase 3A mRNA expression in Egyptian patients with idiopathic thrombocytopenic purpura.
El-Shiekh EH; Bessa SS; Abdou SM; El-Refaey WA
Int J Lab Hematol; 2012 Aug; 34(4):369-76. PubMed ID: 22321265
[TBL] [Abstract][Full Text] [Related]
59. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
Fife BT; Bluestone JA
Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
[TBL] [Abstract][Full Text] [Related]
60. PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment.
Hassan SS; Akram M; King EC; Dockrell HM; Cliff JM
PLoS One; 2015; 10(9):e0137646. PubMed ID: 26359860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
